viewArix Bioscience PLC

Arix Bioscience says portfolio company Autolus Therapeutics prices shares at US$11 each

In total it has put up for sale 7.25mln American Depositary Shares that will bring in a ‘gross’ US$80mln

Arix Bioscience PLC -
Arix is a the venture capital company focused on the biotechnology sector

Arix Bioscience PLC (LON:ARIX), the venture capital company focused on the biotechnology sector, said its portfolio company, Autolus Therapeutics (NASDA:AUTL), has priced its offering of new American Depositary Shares (ADS).

In total it has put up for sale 7.25mln ADSs at a price of US$11 each in an underwritten offer that will bring in a ‘gross’ US$80mln.

The underwriters have a 30-day option to acquire an additional 1.088mln shares.

Arix retains a 6.5% stake worth US$42mln (£32mln) and its chief executive, Dr Joe Anderson, remains on the Autolus board.

Quick facts: Arix Bioscience PLC

Price: 69.95 GBX

Market: LSE
Market Cap: £94.82 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...



Arix Bioscience acquires stake in novel firm developing sickle cell treatment

Arix Bioscience PLC (LON:ARIX) investment associate John Cassidy talks Proactive London through its decision to invest US$15mln (£11.3mln) in Imara - a firm which is developing treatments for sickle cell disease. Through the deal Arix receives a 10% stake in the company while also...

on 19/3/19

2 min read